NYSE:WSTLife Sciences
Biologics Momentum And US$1 Billion Buyback Might Change The Case For Investing In West (WST)
West Pharmaceutical Services recently reported strong first-quarter 2026 results, with net sales up 21% year over year and raised full-year revenue and adjusted EPS guidance, underpinned by high-value biologics components and self-injection delivery devices.
The company also authorized a new US$1.00 billion share repurchase program and executed substantial buybacks, underscoring its role as a critical supplier in injectable-drug infrastructure rather than a traditional packaging...